Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $8.2 million.

  • Whitehawk Therapeutics' Accumulated Expenses fell 4180.07% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 4180.07%. This contributed to the annual value of $14.6 million for FY2024, which is 238.36% up from last year.
  • Whitehawk Therapeutics' Accumulated Expenses amounted to $8.2 million in Q3 2025, which was down 4180.07% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Accumulated Expenses registered a high of $14.9 million during Q4 2022, and its lowest value of $677891.0 during Q2 2021.
  • Its 5-year average for Accumulated Expenses is $9.6 million, with a median of $9.7 million in 2023.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Accumulated Expenses skyrocketed by 120120.5% in 2021, and later plummeted by 6060.65% in 2025.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' Accumulated Expenses stood at $8.7 million in 2021, then surged by 71.46% to $14.9 million in 2022, then fell by 4.13% to $14.3 million in 2023, then increased by 2.38% to $14.6 million in 2024, then tumbled by 43.91% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, $5.4 million for Q2 2025, and $8.6 million during Q1 2025.